
Zepbound (tirzepatide) has received FDA approval for the treatment of obstructive sleep apnea, now included in Medicare coverage to help manage the condition alongside obesity. This approval marks a shift towards a holistic approach, combining medication with real-time monitoring for improved patient outcomes. Introduction FDA Authorization in Healthcare Technology Clinical Trial Successes and Symptom Reduction Weight Loss and Insurance Implications Wesper’s At-Home Sleep Technology IntroductionObstructive sleep apnea currently impacts an estimated 39 million adults in the U.S. This new FDA-approved medication, Zepbound (tirzepatide), seeks to relieve moderate-to-severe symptoms in adults with obesity by improving nighttime breathing and reducing related health risks....
Featured Articles

GLP-1 therapies, such as Zepbound (tirzepatide),...
READ
In primary care, the integration of...
READ
Wesper is poised to change sleep...
READthe WESPER JOURNAL
Discover Our
Clinical Validations
Wesper’s technology is backed by rigorous clinical validations, ensuring accuracy and reliability in sleep health monitoring. Tested against gold-standard sleep studies, Wesper delivers precise data on sleep quality, stages, snoring, and breathing patterns, providing both patients and providers with trusted insights for effective sleep management.

GETTING TO KNOW OUR SLEEP EXPERT
Questions? Dr. Rohrscheib has Answers.
Struggling with undiagnosed sleep apnea? You’ve come to the right place. Dr. Chelsie Rohrscheib, our in-house sleep expert and researcher, provides valuable educational content on conditions associated with sleep apnea and how Wesper can offer solutions to help you take control of your sleep health.